☆
Watchlist
Log in
Sign-up
Radiopharm Theranostics Ltd (rad) Logo

Radiopharm Theranostics Ltd (RAD)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials (10-yr)
Deep Dive
NEW

RAD Chart

Snapshot

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -68.46%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,669 of 2,413
Sector Rank 153 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies SVA / IMC / IME
EPS $0.00
DPS $0.00
Book Value Per Share $0.00

Broker Consensus

RAD is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Date Heading Pages File Size Time

Corporate Overview

Radiopharm Theranostics Limited (RAD) is a Clinical stage radiotherapeutics company which is developing and commercialising a platform of radiopharmaceutical products for both therapeutic and diagnostic applications in precision oncology.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Sydney NSW 2000
Website www.radiopharmtheranostics.com
Registry Automic Group
Auditor Grant Thornton Audit Pty Ltd
Date Listed 25 Nov 2021

Upcoming Calendar (Forecasted)

Date Event
27/02/2023 Report (Interim)
28/04/2023 Report (Quarterly)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.
Show All

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Hester Larkin Non-Executive Director Feb 2022

Ms Hester Larkin

Non-Executive Director

Ms Larkin has legal, pharmaceuticals and medical imaging industry background with experience in governance, risk, acquisitions, mergers, licensing & divestitures. Ms Larkin has a 30-year career spanning both pharmaceuticals and nuclear medicine across Europe, Middle East & Africa, including over 12 years of experience in senior leadership roles in the industry. She has experience in product launches of proprietary pharmaceuticals and imaging agents in oncology, cardiology, neurology and HIV. Ms Larkin is currently Managing Director of Hester Larkin Associates Consulting where she provides consulting services to diagnostic imaging, pharmaceutical and biotech companies in projects ranging from from pre-clinical, clinical, EMA submission, EU medical advisory boards, EU manufacturing and commercial partnerships. She has held several Board Director and Trustee positions in the UK and Belgium and currently sits on the Board of 3 Charities. She was a business consultant at the Cardiac Imaging Department, Wellington Hospital when it launched the first Electron Beam CT (EBCT) centre. Prior to this Ms Larkin was EMEA General Manager BMS Medical Imaging at Bristol-Myers Squibb and had a 19-year career at DuPont Pharmaceuticals holding several roles in European marketing, European Business development and General Management & VP positions. She was the first nonAmerican female to be appointed as Managing Director & Vice President UK & Ireland for Dupont Pharmaceuticals. For 7 years Ms Larkin also chaired an Industry Working Group on Nuclear Medicine Awareness for 'Nuclear Medicine Europe-the Industry Association,' formerly AIPES. She is also a qualified leadership coach.
Mr Riccardo Canevari Chief Executive Officer,Managing Director Sep 2021

Mr Riccardo Canevari

Chief Executive Officer,Managing Director

Mr Canevari has experience across specialty pharmaceuticals, oncology and radiopharmaceuticals. Most recently, he was the Chief Commercial Officer of Novartis company Advanced Accelerator Applications. He was responsible for global commercial strategy and country organisations in approximately 20 countries across North America, Europe and Asia. He assessed Go To Market Models for each priority country and access to other markets. Prior to this, he was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017. He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.
Mr Ian Turner Non-Executive Director Apr 2021

Mr Ian Turner

Non-Executive Director

Mr Turner is an experienced radiopharmaceutical and nuclear medicine supply and manufacturing expert with a C-level career across some of the corporations in the sector including CEO and President of Siemens PETNET Solutions from 2010-2012, where he was recruited to turnaround Siemens underperforming global radiopharmacy lines. Prior to this, he was General Manager of ANSTO Radiopharmaceuticals in Sydney. He was also Executive Director of PETNET Australia Pty Ltd. He spent a decade in various C-level roles at Varian Inc based in Palo Alto and Melbourne. He was also previously a director of Coqui Pharmaceuticals until 2019, a company involved in the supply of radioisotopes in the US. Mr Turner filed for voluntary bankruptcy and became bankrupt on 17 October 2016, consequential to the collapse of Timbercorp Limited and associated entities. Mr Turner was discharged from bankruptcy on 18 October 2019. He is also a member of risk management committee.
Mr Paul Alex Hopper Executive Chairman,Founder,Executive Director Feb 2021

Mr Paul Alex Hopper

Executive Chairman,Founder,Executive Director

Mr Hopper has over 25 years experience in biotech, healthcare and life sciences with a focus on start-up and growth companies. He has served as either Founder, Chairman, non-executive director, or CEO, for more than fifteen companies in the US, Australia and Asia. Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma and Suda Pharmaceuticals. His experience covers fund raising in Australia, Asia, US and Europe, and he has experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances. He is the Founder and Executive Chairman of ASX listed Imugene Limited (ASX:IMU). He licensed the technology from the University of Vienna Medical School in 2012 and listed the company on the ASX in December 2013. He is the Founder of Vaxinia and Chimeric Therapeutics Limited (ASX:CHM). In 2008, he became Chairman of ASX listed Viralytics Limited (ASX:VLA) and is also the Founder of Glioblast. Mr Hopper is also a Founder of ASX listed Prescient Therapeutics Limited.
Dr Michael Baker Non-Executive Director Feb 2021

Dr Michael Baker

Non-Executive Director

Dr Baker is currently CEO and managing director of ASX listed Suda Pharmaceuticals which is developing technologies in the cell therapy and drug delivery fields. Prior to Suda he was an investment manager with Australian life science fund, BioScience Managers and a senior manager at Hexima Limited. He was awarded the Nancy Millis award for the most outstanding thesis for the Faculty of Science, Technology and Engineering in 2010. Dr Baker was also the Alexander von Humbolt Research Fellow at the University of Cologne. He is also a risk management committee Chairperson.
Mr Nathan Jong Joint Company Secretary N/A
Mr Phillip Hains Chief Financial Officer,Joint Company Secretary N/A
Show All

Director Transactions

RAD directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
13/04/22 Paul Hopper Buy +250,000 $0.225 $56,250 On-market trade
12/04/22 Ian Turner Buy +74,805 $0.23 $17,205 On-market trade
11/04/22 Riccardo Canevari Buy +100,000 $0.23 $23,000 On-market trade
11/04/22 Riccardo Canevari Transfer 250,000 $0.22 $55,000 Off-market transfer
11/04/22 Riccardo Canevari Transfer 250,000 $0.22 $55,000 Off-market transfer
25/03/22 Hester Larkin Buy +66,114 $0.26 $17,189 On-market trade
03/03/22 Ian Turner Buy +45,195 $0.32 $14,462 On-market trade
03/03/22 Ian Turner Transfer 184,697 $0.30 $55,409 Off-market transfer
03/03/22 Ian Turner Transfer 184,697 $0.30 $55,409 Off-market transfer
07/01/22 Riccardo Canevari Buy +100,000 $0.37 $37,000 On-market trade
10/12/21 Ian Turner Buy +54,697 $0.353 $19,308 On-market trade
08/12/21 Paul Hopper Buy +200,000 $0.343 $68,500 On-market trade
07/12/21 Riccardo Canevari Buy +150,000 $0.315 $47,250 On-market trade
25/11/21 Ian Turner Buy +130,000 $0.42 $54,618 On-market trade
25/11/21 Paul Hopper Buy +200,000 $0.47 $94,000 On-market trade
Show All

Director Interests

The current holdings of RAD directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Paul Hopper 13/04/2022 400,000 90,250,000 N/A N/A
Ian Turner 12/04/2022 209,167 304,697 1,900,002 N/A
Riccardo Canevari 11/04/2022 4,000,000 350,000 8,666,678 N/A
Hester Larkin 25/03/2022 0 66,114 N/A N/A
Michael Baker 11/02/2021 N/A 39,723 1,900,002 N/A
Show All

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Nov 18, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Kilnwata Investments Limited 90,000,000 35.53%
Nanomab Technologies Limited 21,111,111 8.33%
CS Third Nominees Pty Limited <HSBC Cust Nom AU Ltd 13 A/C> (i) 9,862,888 3.89%
Merrill Lynch Australia Nominees Pty Limited <MLPro A/C> 6,666,667 2.63%
HSBC Custody Nominees 6,003,189 2.37%
Trimt GMBH 4,444,444 1.75%
HSBC Custody Nominees Australia Limited A/C 2 4,124,888 1.63%
Ricardo Canevari 4,000,000 1.58%
CS Third Nominees Pty Limited <HSBC Cust Nom AU Ltd 13 A/C> (ii) 3,333,334 1.32%
Citicorp Nominees Pty Limited 3,315,687 1.31%
Brispot Nominees Pty Ltd <House Head Nominee A/C> 3,000,000 1.18%
Thorney Technologies Ltd 2,888,889 1.14%
Tiga Trading Pty Ltd 2,888,889 1.14%
Mr Richard John Mann 2,083,500 0.82%
Carnport Pty Limited 1,777,778 0.70%
Frazis Capital Partners 1,666,667 0.66%
J P Morgan Nominees Australia Pty Limited 1,666,667 0.66%
One Managed Investments Fund Ltd <Fifth Estate Emerging Companies A/C> 1,666,667 0.66%
Australian Direct Investment Pty Limited <Super Fund A/C> 1,334,167 0.53%
WACC Pty Ltd <Progressive Global A/C> 1,333,334 0.53%
UBS Nominees Pty Ltd 1,333,333 0.53%
National Nominees Limited 1,167,960 0.46%
Portfolio Nominees Pty Ltd 1,083,500 0.43%
Show All

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 0 61 180 936 185 1,362

Substantial Shareholders

No Substantial Shareholders for RAD in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
22-02-22 NanoMab Technology Limited 5,888,798 8.33 10.70

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
RAD Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.